Annexon, Inc.

Annexon did not provide quarterly revenue, EPS, gross margin, or other standard operating financial figures on this business update call. On the clinical side, the company said the first cohort in FORWARD included 10 patients treated with a single 30 mg/kg infusion of tanruprubart, and that all 10 improved rapidly; 4 bed-bound patients regained the ability to walk and 1 ventilated patient was weaned within 4 days. In ARCHER II, 659 patients were enrolled, discontinuation was under 10%, and dosing compliance was above 95%. Management said the company entered an Oxford Finance credit facility for up to $200 million of non-dilutive capital, extending cash runway into 2028. Forward-looking guidance: tanruprubart remains on track for a U.S. BLA submission in the fourth quarter of this year, and ARCHER II’s month 15 primary endpoint readout is expected in the fourth quarter of this year. If the study is positive at month 15, separate substudy analysis results would be expected in the first quarter of 2027, and the full ARCHER II study including month 24 analysis is expected to complete in the third quarter of 2027.

Doug Love framed Annexon as entering a pivotal period where decades of C1q biology can translate into multiple potential medicines. He was very upbeat about both programs, saying tanruprubart “flat-out works” in GBS and that the month 24 GA endpoint builds a stronger franchise, a “moat,” without weakening the month 15 readout. His tone was confident and promotional, but he also stressed the decisions were made after strong trial execution and after crossing key internal milestones like 12 months of follow-up.

Jen Lew did not deliver a detailed financial review on the call, and no revenue or EPS figures were discussed. The key balance sheet item was the Oxford Finance facility providing access to up to $200 million of non-dilutive capital, which management said extends runway into 2028 and improves financial flexibility. Management described the capital as supporting preparation for global commercialization and diversifying the capital structure, but no cash balance, burn rate, or margin data were given.

The most notable Q&A centered on the added month 24 endpoint in ARCHER II and whether it signaled any concern about month 15. Management said regulators in the U.S. and Europe had been clear that if Annexon wants month 24 efficacy in the label, it must alpha-allocate to month 24, and they repeatedly said month 15 remains their base case and that masked event rates are tracking to plan. Analysts also asked whether the month 24 move was driven by blinded data; management said it was not a sign of concern, but rather a strategic use of extra power from overenrollment and low dropout, plus strong execution. On GBS, management said it is in ongoing discussions with the FDA and feels confident about a Q4 BLA filing with the addition of FORWARD data.